Marimed (MRMD) Depreciation & Amortization (CF) (2016 - 2026)

Marimed (MRMD) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 10.26% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $8.7 million, a 9.98% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 2.52% from the prior year.
• Depreciation & Amortization (CF) was $2.3 million for Q2 2026 at Marimed, up from $2.2 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.3 million in Q2 2026 and troughed at $702000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 96.55% in 2024 and fell 6.76% in 2025, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $963000.0 in 2022, then surged by 77.67% to $1.7 million in 2023, then grew by 26.3% to $2.2 million in 2024, then decreased by 4.07% to $2.1 million in 2025, then advanced by 12.45% to $2.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.3 million (Q2 2026), $2.2 million (Q1 2026), and $2.1 million (Q4 2025), per Business Quant data.